The KRAS inhibitor market was valued at US$ 108 million in 2023. During the forecast period, the market is expected to garner a 5.5% CAGR. By 2034, the gold metalized market is expected to reach a valuation of US$ 196 million.
Report Attribute
Details
Estimated Market Value in 2023
US$ 108 million
Expected Market Value in 2024
US$ 115.2 million
Projected Forecast Value in 2034
US$ 196 million
Anticipated Growth Rate from 2024 to 2034
5.5%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Demand Analysis of KRAS Inhibitors
The market players in the global KRAS inhibitor market are aimed at developing investigational drug candidates for the mutant KRAS. A key player has developed MRTX1133 which is used for the inhibition of KRASG12D. This candidate holds a strong potential to be a first of its kind therapeutic.
The development of KRAS inhibitor based combination treatments presents an opportunity. Improved patient outcomes, increased tumor response rates, and synergistic benefits may result from combining KRAS inhibitors alongside other targeted treatments, immunotherapies, or traditional chemotherapeutic drugs.
Exploring and implementing these combination techniques might result in innovative therapy regimens with improved efficacy against KRAS-mutated tumors, addressing unmet medical needs and widening the therapeutic environment in oncology.
KRAS Inhibitor Market Historical Analysis from 2019 to 2023 vs. Forecast Outlook from 2024 to 2034
In 2019, the global KRAS inhibitor market was estimated to reach a valuation of US$ 81.8 million, according to a report from Future Market Insights. The KRAS inhibitor market witnessed significant growth, registering a CAGR of 7.20% during the historical period, 2019 to 2023.
Historical CAGR from 2019 to 2023
7.20%
Forecast CAGR from 2024 to 2034
5.5%
The development of covalent inhibitors that specifically target specific KRAS mutants is a significant development in the KRAS inhibitor market. Traditional inhibitors frequently fail to target KRAS due to its complex structure and dynamic activity.
Covalent inhibitors may provide improved selectivity and effectiveness by forming a solid, permanent connection with their target. With the potential to provide patients with KRAS-driven tumors with more effective treatment choices, these covalent inhibitors mark a substantial advancement in KRAS-targeted therapy.
Find your sweet spots for generating winning opportunities in this market.
Significant Drivers of the KRAS Inhibitor Market
Innovative Drug Delivery Technologies to Support Market Demand
The KRAS inhibitor market is being driven by the development of innovative medication delivery systems. These innovative delivery methods increase the bioavailability and targeted administration of KRAS inhibitors. This helps in boosting their effectiveness and lowering the possibility of negative side effects.
These advances, which overcome difficulties such as low solubility and quick clearance, pave the path for more effective KRAS inhibitor treatment, improving their clinical relevance and, eventually, aiding patients with KRAS-mutated malignancies.
Factors which can Challenge the Market Growth
Poor Bioavailability and Inactivity of Cancer Cells to Restrict the Market Growth
Few of the inhibitors have been proven to show poor bioavailability, which delays the absorption of drugs. For instance, ARS-853, one of the first KRAS inhibitors developed not only had a lower bioavailability but also a shorter metabolic plasma stability.
KRAS inhibitors can at times fail to target all the cancer cells at the same time. In such a situation, this can lead to proliferation of the cancer cells at a faster pace. Such factors can impede the market growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Comparative View of Adjacent Markets
In this section, analysis will be drawn among three relevant markets. These are the KRAS inhibitor Market, lung cancer therapeutics market and cancer diagnostics market.
Globally increasing cancer incidence rates, increased need for precision treatment, and developing biotechnology advancements are the main drivers of these markets. The growth of these markets is attributed to rising knowledge of early detection techniques, regulatory frameworks that are supportive, and increased research spending.
The constant development and adoption of innovative treatments and diagnostic technologies is fueled by the necessity to meet unmet medical requirements and enhance patient outcomes.
KRAS Inhibitor Market:
Market Name
KRAS Inhibitor Market
CAGR from 2024 to 2034
5.5%
Growth Factor
Increased research and development towards investing new candidates to combat the KRAS mutant proteins.
Future Opportunities
Partnerships can be quite effective for the market players to grow regionally.
Lung Cancer Therapeutics Market:
Market Name
Lung Cancer Therapeutics Market
CAGR from 2024 to 2034
13.5%
Growth Factor
The demand for lung cancer therapeutics is being driven by the development of nanomedicine as a lung cancer therapy and the increasing number of approvals within the lung cancer treatments market.
Future Opportunities
The lung cancer therapeutics market is expected to grow due to an increase in regulatory approvals and the adoption of modern treatments in Europe.
Cancer Diagnostics Market:
Market Name
Cancer Diagnostics Market
CAGR from 2024 to 2034
8.5%
Growth Factor
In developed countries, the market is expected to be driven in the upcoming years by increasing infrastructure for diagnostic laboratories.
Future Opportunities
Future market development is anticipated to be driven by a rise in government initiatives as well as those of other private organizations to increase awareness about early cancer detection and prevention.
Category wise Insights
This section focuses on providing detailed analysis of two particular market segments for KRAS inhibitor, the dominant cancer type and the significant end user. The two main segments discussed below are the pancreatic cancer and cancer diagnostic centers.
KRAS Inhibitor is likely to be Widely Employed for Pancreatic Cancer Treatments
Cancer Type
Pancreatic Cancer
CAGR from 2024 to 2034
5.3%
During the forecast period, the KRAS inhibitors are anticipated to be widely used for treating pancreatic cancer. Since KRAS mutations are present in almost 90% of pancreatic tumors, targeted medicines such as KRAS inhibitors provide a promising way to combat the illness.
These inhibitors have the ability to precisely target the abnormal signaling pathways caused by KRAS mutations, which may slow the development of tumors and increase patient survival rates. Their ability to effectively combat pancreatic cancers with KRAS mutations makes them an indispensable part of any therapy plans for pancreatic cancer in the future.
Cancer Diagnostic Centers will be the Dominant end User of KRAS Inhibitors
End User
Cancer Diagnostic Centers
CAGR from 2024 to 2034
5.1%
During the forecast period, the cancer diagnostic center will be utilizing the KRAS inhibitors widely. KRAS inhibitors are being widely used in cancer diagnostic centers to precisely identify patients with KRAS mutations, allowing for customized treatment methods.
Early diagnosis of these mutations is made easier by including KRAS inhibitor testing into diagnostic processes. This helps with prognostication as well as treatment decision-making, which ultimately improves patient outcomes and raises the standard of cancer care.
Region wise Analysis
This section will go into detail on the KRAS inhibitor markets in a few key countries, including the United States, the United Kingdom, China, Japan and South Korea. This sector will lay emphasis on the various reasons that are propelling the growth of KRAS inhibitors in the below mentioned regions.
Countries
Forecast CAGRs from 2024 to 2034
The United States
5.7%
The United Kingdom
6.5%
China
6.2%
Japan
7%
South Korea
6.9%
Robust Research in the Field of Mutant KRAS Proteins to Propel Growth
The United States KRAS inhibitor ecosystem is anticipated to gain a CAGR of 5.7% through 2034. For instance, researchers from AstraZeneca have discovered a new drug candidate, AZD4747, which shows promise in treating tumors with the KRAS G12C mutation.
This mutation limits the ability of the GTPase KRAS to hydrolyze GTP to the inactive GDP-bound state, resulting in the constitutive activation of downstream signaling pathways.
The AstraZeneca research team discovered AZD4747, a highly effective and selective KRAS G12C inhibitor, using a structure-based drug development approach. Drug potency, drug metabolism, and pharmacokinetics (DMPK) characteristics were all optimized for the drug candidate.
Agreements with Companies from other Regions to Enhance Demand
The KRAS inhibitor market in the United Kingdom is expected to expand with a 6.5% CAGR through 2034. The regional companies are forging partnerships with companies outside the United Kingdom to boost their oncology pipeline.
For instance, the United Kingdom based Biotech Company RedX Pharma announced that it has entered an agreement with Jazz Pharmaceuticals, based out of Ireland. This was done to transfer the preclinical KRAS inhibitor program's global rights.
Under the conditions of the agreement, Redx Pharma will provide JAZZ an upfront payment of $10 million. This will be in return for all rights, patents, and interests pertaining to its exclusive KRAS inhibitor program, which includes its pan- and G12D-specific KRAS compounds.
Government Initiatives in China towards Better Healthcare to Propel Demand
The KRAS inhibitor ecosystem in China is anticipated to develop with a 6.2% CAGR from 2024 to 2034. As part of its wider healthcare reforms, the Chinese government has actively promoted and invested in the biotechnology and pharmaceutical industries.
The government's goals with the Made in China 2025 plan as well as the Healthy China 2030 policy are to solve healthcare issues and improve domestic innovation capacities.
Funding research and development in fields like cancer therapeutics, including KRAS inhibitors, is part of this. The development and marketing of KRAS inhibitors in China might be expedited by government financing, favorable policies, along with regulatory reforms.
Booming Pharmaceutical Sector in Japan to Push Demand for KRAS Inhibitor
The KRAS inhibitor industry in Japan is anticipated to reach a 7% CAGR from 2024 to 2034. Japan has a thriving pharmaceutical sector, with several major companies engaged in the research and development of new drugs.
These companies have an abundance of knowledge and resources devoted to cancer and other medicinal research and innovation. Japanese pharmaceutical companies are investing in the research and development of KRAS inhibitors as potential treatments for different cancers, with an emphasis on precision medicine and customized therapy.
Biotech Innovations in South Korea to Propel Demand
The South Korea KRAS inhibitor ecosystem is anticipated to expand with a 6.9% CAGR during the forecast period. The biotechnology sector in South Korea is expanding quickly, with a particular emphasis on developing innovative treatments for a range of diseases, including cancer.
The country boasts a robust biotech workforce with advanced skills and a robust research infrastructure. Investing in biotech firms and research institutes helps to discover new treatments, including KRAS inhibitors, which have the potential to cure malignancies caused by mutations in the KRAS gene.
Market Competition
Market players are experimenting with various kinds of KRAS inhibitors for better outcomes to treat cancer patients. Companies are drifting towards researching with two forms, KRASG12C inhibitor and KRASG12D Inhibitor.
For instance, Adagrasib, which Mirati is developing, is intended to specifically target the KRASG12C mutation and optimize inhibition by trapping the mutant protein in an irreversible state. Adagrasib is one of the company’s highly selective, investigational and potent oral small molecule therapy.
Preclinical research has demonstrated that adagrasib produced significantly stronger anti-tumor activity when combined with a wide variety of medicines, such as SHP2, PD-1, Pan-EGFR, CDK 4/6, and SOS1 inhibitors.
The objective of the market players is to maximize effectiveness and avoid treatment resistance. They also want to make sure that patients may benefit from these potentially helpful combination treatments for the duration of their therapy. The key players in this market include:
Amgen
Boehringer Ingelheim
BridgeBio Pharma
Erasca
Innovent Biologics Inc.
Incyte
Mirati Therapeutics
Novartis
Jemincare
Cardiff Oncology Inc.
Key Developments
In 2024, Amgen revealed new data from its CodeBreaK trial program at the ASCO Annual Meeting, emphasizing the effectiveness of LUMAKRAS®/LUMYKRAS® (sotorasib). The results were based on advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC).
A major development in KRAS inhibitor therapy was demonstrated by the Amgen-funded SCARLET research. It demonstrated sotorasib's safety and effectiveness when combined with platinum-based chemotherapy for the frontline treatment of advanced NSCLC with a KRAS G12C mutation.
Key Coverage in KRAS Inhibitor Market Report
Oncology KRAS-targeting therapy market
Global Kirsten Rat Sarcoma (KRAS) Market
KRAS Inhibitor lung cancer
KRAS Inhibitor FDA approval
Report Scope
Report Attribute
Details
Growth Rate
CAGR of 5.5% from 2024 to 2034
Market value in 2024
US$ 115.2 million
Market value in 2034
US$ 196 million
Base Year for Estimation
2023
Historical Data
2019 to 2023
Forecast Period
2024 to 2034
Quantitative Units
US$ million for value
Report Coverage
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Cancer Type
End User
Region
Regions Covered
North America
Latin America
Western Europe
Eastern Europe
South Asia and Pacific
East Asia
The Middle East & Africa
Countries Profiled
The United States
Canada
Brazil
Mexico
Germany
The United Kingdom
France
Spain
Italy
Poland
Russia
Czech Republic
Romania
India
Bangladesh
Australia
New Zealand
China
Japan
South Korea
GCC Countries
South Africa
Israel
Key Companies Profiled
Amgen
Boehringer Ingelheim
BridgeBio Pharma
Erasca
Innovent Biologics Inc.
Incyte
Mirati Therapeutics
Novartis
Jemincare
Cardiff Oncology Inc.
Customisation Scope
Available on Request
Key Segments Profiled in the KRAS Inhibitor Market
By Cancer Type:
Lung Cancer
Pancreatic Cancer
Colorectal Cancer
Others
By End User:
Clinic Laboratories
Cancer Diagnostic Centres
Hospitals
Cancer Research Institutes
Academic Institutions
Others
By Region:
North America
Latin America
Western Europe
Eastern Europe
South Asia and Pacific
East Asia
The Middle East & Africa
Frequently Asked Questions
What is the anticipated growth rate of the KRAS inhibitor market from 2024 to 2034?
The KRAS inhibitor market is expected to garner a 5.5% CAGR from 2024 to 2034.
What will be the global market outlook for KRAS inhibitor through 2024?
By 2024, the global KRAS inhibitor market is likely to gain US$ 115.2 million.
What is the expected global market valuation for KRAS inhibitor by 2034?
By 2034, the KRAS inhibitor market valuation is likely to reach a sum of US$ 196 million.
How will the demand for KRAS inhibitors develop in the United States?
The KRAS inhibitor industry in the United States is likely to garner a 5.7% CAGR during the forecast period.
Which cancer type will use the KRAS inhibitor widely?
The KRAS inhibitor will be widely used for the treatment of pancreatic cancer, along with an anticipated 5.3% CAGR through 2034.
Which institution will be the dominant end user in the KRAS inhibitor market?
The cancer diagnostic centers are likely to be the dominant end users of the KRAS inhibitor, with an expected 5.1% CAGR through 2034.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023
4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Cancer Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Cancer Type, 2019 to 2023
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Cancer Type, 2024 to 2034
5.3.1. Lung Cancer
5.3.2. Pancreatic Cancer
5.3.3. Colorectal Cancer
5.3.4. Others
5.4. Y-o-Y Growth Trend Analysis By Cancer Type, 2019 to 2023
5.5. Absolute $ Opportunity Analysis By Cancer Type, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End-User, 2019 to 2023
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User, 2024 to 2034
6.3.1. Clinic Laboratories
6.3.2. Cancer Diagnostic Centres
6.3.3. Hospitals
6.3.4. Cancer Research Institutes
6.3.5. Academic Institutions
6.3.6. Others
6.4. Y-o-Y Growth Trend Analysis By End-User, 2019 to 2023
6.5. Absolute $ Opportunity Analysis By End-User, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Cancer Type
8.2.3. By End-User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Cancer Type
8.3.3. By End-User
8.4. Key Takeaways
9. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Cancer Type
9.2.3. By End-User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Cancer Type
9.3.3. By End-User
9.4. Key Takeaways
10. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Cancer Type
10.2.3. By End-User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Cancer Type
10.3.3. By End-User
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Cancer Type
11.2.3. By End-User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Cancer Type
11.3.3. By End-User
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Cancer Type
12.2.3. By End-User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Cancer Type
12.3.3. By End-User
12.4. Key Takeaways
13. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Cancer Type
13.2.3. By End-User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Cancer Type
13.3.3. By End-User
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Cancer Type
14.2.3. By End-User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Cancer Type
14.3.3. By End-User
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Market Share Analysis, 2023
15.1.1.1. By Cancer Type
15.1.1.2. By End-User
15.2. Canada
15.2.1. Market Share Analysis, 2023
15.2.1.1. By Cancer Type
15.2.1.2. By End-User
15.3. Brazil
15.3.1. Market Share Analysis, 2023
15.3.1.1. By Cancer Type
15.3.1.2. By End-User
15.4. Mexico
15.4.1. Market Share Analysis, 2023
15.4.1.1. By Cancer Type
15.4.1.2. By End-User
15.5. Germany
15.5.1. Market Share Analysis, 2023
15.5.1.1. By Cancer Type
15.5.1.2. By End-User
15.6. UK
15.6.1. Market Share Analysis, 2023
15.6.1.1. By Cancer Type
15.6.1.2. By End-User
15.7. France
15.7.1. Market Share Analysis, 2023
15.7.1.1. By Cancer Type
15.7.1.2. By End-User
15.8. Spain
15.8.1. Market Share Analysis, 2023
15.8.1.1. By Cancer Type
15.8.1.2. By End-User
15.9. Italy
15.9.1. Market Share Analysis, 2023
15.9.1.1. By Cancer Type
15.9.1.2. By End-User
15.10. Poland
15.10.1. Market Share Analysis, 2023
15.10.1.1. By Cancer Type
15.10.1.2. By End-User
15.11. Russia
15.11.1. Market Share Analysis, 2023
15.11.1.1. By Cancer Type
15.11.1.2. By End-User
15.12. Czech Republic
15.12.1. Market Share Analysis, 2023
15.12.1.1. By Cancer Type
15.12.1.2. By End-User
15.13. Romania
15.13.1. Market Share Analysis, 2023
15.13.1.1. By Cancer Type
15.13.1.2. By End-User
15.14. India
15.14.1. Market Share Analysis, 2023
15.14.1.1. By Cancer Type
15.14.1.2. By End-User
15.15. Bangladesh
15.15.1. Market Share Analysis, 2023
15.15.1.1. By Cancer Type
15.15.1.2. By End-User
15.16. Australia
15.16.1. Market Share Analysis, 2023
15.16.1.1. By Cancer Type
15.16.1.2. By End-User
15.17. New Zealand
15.17.1. Market Share Analysis, 2023
15.17.1.1. By Cancer Type
15.17.1.2. By End-User
15.18. China
15.18.1. Market Share Analysis, 2023
15.18.1.1. By Cancer Type
15.18.1.2. By End-User
15.19. Japan
15.19.1. Market Share Analysis, 2023
15.19.1.1. By Cancer Type
15.19.1.2. By End-User
15.20. South Korea
15.20.1. Market Share Analysis, 2023
15.20.1.1. By Cancer Type
15.20.1.2. By End-User
15.21. GCC Countries
15.21.1. Market Share Analysis, 2023
15.21.1.1. By Cancer Type
15.21.1.2. By End-User
15.22. South Africa
15.22.1. Market Share Analysis, 2023
15.22.1.1. By Cancer Type
15.22.1.2. By End-User
15.23. Israel
15.23.1. Market Share Analysis, 2023
15.23.1.1. By Cancer Type
15.23.1.2. By End-User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Cancer Type
16.3.3. By End-User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Amgen
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Boehringer Ingelheim
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. BridgeBio Pharma
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Erasca
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Innovent Biologics, Inc.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Incyte
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Mirati Therapeutics
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Novartis
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Jemincare
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Cardiff Oncology, Inc.
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used19. Research Methodology
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2019 to 2034
Table 2: Global Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034
Table 3: Global Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 4: North America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 5: North America Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034
Table 6: North America Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 8: Latin America Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034
Table 9: Latin America Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 10: Western Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 11: Western Europe Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034
Table 12: Western Europe Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 13: Eastern Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 14: Eastern Europe Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034
Table 15: Eastern Europe Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 16: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 17: South Asia and Pacific Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034
Table 18: South Asia and Pacific Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 19: East Asia Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 20: East Asia Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034
Table 21: East Asia Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 22: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 23: Middle East and Africa Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034
Table 24: Middle East and Africa Market Value (US$ Million) Forecast by End-User, 2019 to 2034
List of Charts
Figure 1: Global Market Value (US$ Million) by Cancer Type, 2024 to 2034
Figure 2: Global Market Value (US$ Million) by End-User, 2024 to 2034
Figure 3: Global Market Value (US$ Million) by Region, 2024 to 2034
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2019 to 2034
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2024 to 2034
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2024 to 2034
Figure 7: Global Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034
Figure 8: Global Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034
Figure 9: Global Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034
Figure 10: Global Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 11: Global Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 12: Global Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 13: Global Market Attractiveness by Cancer Type, 2024 to 2034
Figure 14: Global Market Attractiveness by End-User, 2024 to 2034
Figure 15: Global Market Attractiveness by Region, 2024 to 2034
Figure 16: North America Market Value (US$ Million) by Cancer Type, 2024 to 2034
Figure 17: North America Market Value (US$ Million) by End-User, 2024 to 2034
Figure 18: North America Market Value (US$ Million) by Country, 2024 to 2034
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 22: North America Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034
Figure 23: North America Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034
Figure 24: North America Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034
Figure 25: North America Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 26: North America Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 27: North America Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 28: North America Market Attractiveness by Cancer Type, 2024 to 2034
Figure 29: North America Market Attractiveness by End-User, 2024 to 2034
Figure 30: North America Market Attractiveness by Country, 2024 to 2034
Figure 31: Latin America Market Value (US$ Million) by Cancer Type, 2024 to 2034
Figure 32: Latin America Market Value (US$ Million) by End-User, 2024 to 2034
Figure 33: Latin America Market Value (US$ Million) by Country, 2024 to 2034
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 37: Latin America Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034
Figure 40: Latin America Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 41: Latin America Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 43: Latin America Market Attractiveness by Cancer Type, 2024 to 2034
Figure 44: Latin America Market Attractiveness by End-User, 2024 to 2034
Figure 45: Latin America Market Attractiveness by Country, 2024 to 2034
Figure 46: Western Europe Market Value (US$ Million) by Cancer Type, 2024 to 2034
Figure 47: Western Europe Market Value (US$ Million) by End-User, 2024 to 2034
Figure 48: Western Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 49: Western Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 50: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 51: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 52: Western Europe Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034
Figure 53: Western Europe Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034
Figure 54: Western Europe Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034
Figure 55: Western Europe Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 56: Western Europe Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 57: Western Europe Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 58: Western Europe Market Attractiveness by Cancer Type, 2024 to 2034
Figure 59: Western Europe Market Attractiveness by End-User, 2024 to 2034
Figure 60: Western Europe Market Attractiveness by Country, 2024 to 2034
Figure 61: Eastern Europe Market Value (US$ Million) by Cancer Type, 2024 to 2034
Figure 62: Eastern Europe Market Value (US$ Million) by End-User, 2024 to 2034
Figure 63: Eastern Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 64: Eastern Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 65: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 66: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 67: Eastern Europe Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034
Figure 68: Eastern Europe Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034
Figure 69: Eastern Europe Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034
Figure 70: Eastern Europe Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 71: Eastern Europe Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 72: Eastern Europe Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 73: Eastern Europe Market Attractiveness by Cancer Type, 2024 to 2034
Figure 74: Eastern Europe Market Attractiveness by End-User, 2024 to 2034
Figure 75: Eastern Europe Market Attractiveness by Country, 2024 to 2034
Figure 76: South Asia and Pacific Market Value (US$ Million) by Cancer Type, 2024 to 2034
Figure 77: South Asia and Pacific Market Value (US$ Million) by End-User, 2024 to 2034
Figure 78: South Asia and Pacific Market Value (US$ Million) by Country, 2024 to 2034
Figure 79: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 80: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 81: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 82: South Asia and Pacific Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034
Figure 83: South Asia and Pacific Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034
Figure 84: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034
Figure 85: South Asia and Pacific Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 86: South Asia and Pacific Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 87: South Asia and Pacific Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 88: South Asia and Pacific Market Attractiveness by Cancer Type, 2024 to 2034
Figure 89: South Asia and Pacific Market Attractiveness by End-User, 2024 to 2034
Figure 90: South Asia and Pacific Market Attractiveness by Country, 2024 to 2034
Figure 91: East Asia Market Value (US$ Million) by Cancer Type, 2024 to 2034
Figure 92: East Asia Market Value (US$ Million) by End-User, 2024 to 2034
Figure 93: East Asia Market Value (US$ Million) by Country, 2024 to 2034
Figure 94: East Asia Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 95: East Asia Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 97: East Asia Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034
Figure 98: East Asia Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034
Figure 99: East Asia Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034
Figure 100: East Asia Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 101: East Asia Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 102: East Asia Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 103: East Asia Market Attractiveness by Cancer Type, 2024 to 2034
Figure 104: East Asia Market Attractiveness by End-User, 2024 to 2034
Figure 105: East Asia Market Attractiveness by Country, 2024 to 2034
Figure 106: Middle East and Africa Market Value (US$ Million) by Cancer Type, 2024 to 2034
Figure 107: Middle East and Africa Market Value (US$ Million) by End-User, 2024 to 2034
Figure 108: Middle East and Africa Market Value (US$ Million) by Country, 2024 to 2034
Figure 109: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 110: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 111: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 112: Middle East and Africa Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034
Figure 113: Middle East and Africa Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034
Figure 114: Middle East and Africa Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034
Figure 115: Middle East and Africa Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 116: Middle East and Africa Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 117: Middle East and Africa Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 118: Middle East and Africa Market Attractiveness by Cancer Type, 2024 to 2034
Figure 119: Middle East and Africa Market Attractiveness by End-User, 2024 to 2034
Figure 120: Middle East and Africa Market Attractiveness by Country, 2024 to 2034
